-The Times of India NEW DELHI: Days before final hearings on petitions challenging the validity of 'triple talaq', the Supreme Court sought on Monday the Centre's and four states' response on a PIL seeking a ban on the ritual of female genital mutilation (FGM) in the Dawoodi Bohra community. A bench of Chief Justice J S Khehar and Justice D Y Chandrachud and Justice Sanjay Kishan Kaul issued notice to four central...

-The Hindu Online media companies don’t take responsibility for their content, he says Sam Pitroda, regarded as the father of India’s telecom revolution, says that he is deeply concerned with the way social media is being misused globally to propagate lies, hatred and false ideas. In an interview, Mr. Pitroda says that in India also, social media has not been used effectively and technology is not meant to be misapplied. He says...

-The Hindu Business line It must focus on human security and societal development rather than feed the avarice of a golden ghetto minority The discipline of economics has long been obsessed with gross domestic product as the base measure of development. Contemporary economic globalisation and its dominant neoliberal ideology see other considerations as not worth more than a passing glance. Neoliberalism, which used to be referred to as the Washington Consensus, was promoted by...

-The Times of India NEW DELHI: Acknowledging that women are a disadvantaged section despite comprising nearly half of the population of the country, the Centre is considering lowering income tax for single women, introducing Aadhaar-linked Health cards for free basic Health check-ups for women and cashless medical service for those who are pregnant. A national policy for women, framed by a group of ministers headed by external affairs minister Sushma Swaraj, is...

-The Telegraph New Delhi: The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries. It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin's lymphoma, and trastuzumab, used to treat breast cancer. The pre-qualification process is a mechanism...